LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
VNRX
VolitionRx Limited
There isn't enough reported data to score VNRX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VNRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
VNRX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VNRX PE Valuation
VNRX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
VNRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect VNRX's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over VNRX on earnings quality, reporting a profit while its opponent remains loss making.
VNRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.00 | +$1.81 |
| Q2 2026 | -$3.79 | +$1.27 |
| Q1 2026 | -$4.14 | +$1.24 |
| Q4 2025 | -$4.37 | +$1.83 |
| Q3 2022 | -$11.48 | -$2.48 |
| Q2 2022 | -$11.37 | -$3.17 |
| Q1 2022 | -$10.67 | -$2.07 |
| Q4 2021 | -$10.20 | -$1.20 |
VNRX is still losing money, but far less than before: $3.00 per share over the past year, against $11.48 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over VNRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over VNRX on profitability, with a higher operating margin.
VNRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | +157% |
| Q2 2026 | $398.7K | -2% |
| Q1 2026 | $985.1K | +300% |
| Q4 2025 | $447K | +133% |
| Q3 2025 | $627.3K | +32% |
| Q2 2025 | $406.7K | +2.8% |
| Q1 2025 | $246.4K | +44% |
| Q4 2024 | $191.7K | -21% |
VNRX's revenue is growing: $2M last quarter, up 157% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -207% | +607 points |
| Q2 2026 | -1043% | +506 points |
| Q1 2026 | -543% | +1698 points |
| Q4 2025 | -1078% | +1939 points |
| Q3 2025 | -813% | +424 points |
| Q2 2025 | -1549% | +218 points |
| Q1 2025 | -2241% | +2647 points |
| Q4 2024 | -3017% | +566 points |
VNRX's operating margin was −207% last quarter, up 607 points from the same quarter a year ago, near the top of its range since 2020.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over VNRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
VNRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.6M | -$1M |
| Q2 2026 | -$5.2M | +$1.2M |
| Q1 2026 | -$5.3M | -$989.5K |
| Q4 2025 | -$5.5M | +$1.5K |
| Q3 2025 | -$3.6M | +$1.9M |
| Q2 2025 | -$6.3M | +$431.9K |
| Q1 2025 | -$4.3M | +$4.1M |
| Q4 2024 | -$5.5M | -190% |
VNRX has burned cash in almost every quarter: −$21M over the past year, against −$20M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VNRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VNRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +106% | +9.7M shares |
| 1 year | +249% | +13.5M shares |
| 3 years | +380% | +15M shares |
| 5 years | +611% | +16.2M shares |
| Available history | +865% | +16.9M shares |
VNRX has 19M diluted shares, up 249% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $31,772 |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VNRX Net Leverage
VNRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VNRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 4.8 | Oversold |
VNRX's weekly RSI is 24 (oversold) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VNRX PE vs Healthcare Sector
VNRX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over VNRX on trend strength, trading above more of its moving averages.
VNRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.20 | 10% below |
| 20 week MA | $0.52 | 65% below |
| 50 week MA | $2.51 | 93% below |
| 100 week MA | $7.06 | 97% below |
| 200 week MA | $14.3 | 99% below |
VNRX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VNRX on returns for 2026, with the stronger performance.
VNRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.0 | $86.6 | -5.9% |
| 2021 | $86.6 | $64.8 | -25% |
| 2022 | $64.8 | $49.0 | -24% |
| 2023 | $49.0 | $14.3 | -71% |
| 2024 | $14.3 | $12.3 | -14% |
| 2025 | $12.3 | $5.00 | -59% |
| 2026 YTD | $5.00 | $0.18 | -96% |
VNRX has finished every year since 2020 lower, and it's down 96% so far in 2026.